How to Structure a Medicare DMEPOS Compliance Deal Without Losing Your Supplier Status

Suppliers of durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) are facing a more exacting enforcement environment. When a compliance problem arises, the way a supplier structures a resolution with Medicare or its contractors can determine whether the business survives with billing privileges intact or faces revocation. The central challenge is balancing admission of noncompliance against the risk of losing supplier status altogether.

Recent Trends in DMEPOS Oversight

Medicare Administrative Contractors (MACs) and program integrity contractors have intensified pre- and post-payment reviews. In recent quarters, suppliers have reported tighter scrutiny on medical necessity documentation, face-to-face encounter requirements, and proof of delivery. Compliance issues that once resulted in recoupment demands are now more frequently escalating to referral for revocation or a denial of the supplier’s billing privileges.

Another notable trend is the increased use of data analytics to flag billing anomalies. Suppliers who have been in the program for years may suddenly face a targeted review that identifies recurring errors. The resulting settlement discussions are often framed as a “voluntary disclosure” or a negotiated repayment agreement, but the supplier must ensure the deal does not include waiver of the right to maintain enrollment.

Background: What a Compliance Deal Actually Involves

Within the Medicare DMEPOS context, a compliance deal generally refers to a negotiated agreement between a supplier and a contractor to resolve identified violations. This can take several forms, including a repayment plan for overpayments, a corrective action plan, or a settlement agreement that includes specific operational changes. The Legal basis for these arrangements rests on Medicare program integrity rules, supplier standards, and provider enrollment requirements.

DMEPOS suppliers must meet 41 supplier standards, which range from maintaining proper licensure to ensuring appropriate wi-fi inventory controls. Failure to satisfy these standards can trigger a denial of enrollment, a revocation, or, in the context of a compliance deal, design of a corrective action plan. The stakes are especially high because a revocation can lead to a re-enrollment bar that may last for a decade, or longer in cases involving fraud.

Key Concerns for Suppliers

When structuring a compliance deal, suppliers must weigh several risks. A poorly designed agreement may do little to protect the supplier’s status, even if it resolves an immediate overpayment.

• Loss of billing privileges: Any settlement that includes a finding of noncompliance could be referenced in future enforcement actions, making it harder to prove current compliance.
• Concession without resolution: A supplier may agree to a significant repayment but receive nothing in return beyond the current case closing, leaving their enrollment vulnerable to future revocation.
• Admissions of intent: Compliance deal language should avoid admissions of willful misconduct unless necessary, as such language can trigger a more severe re-enrollment bar.
• Surety bond requirements: Regardless of the deal terms, suppliers must maintain evidence of a sufficient surety bond. A lapse during settlement negotiations can cause immediate revocation.
• Impact on referral patterns: Suppliers that accept overly restrictive corrective action plans may inadvertently limit their ability to serve certain patients or accept orders from particular physicians.

Structuring the Compliance Deal Effectively

The goal of a compliance deal is to resolve the identified issue while preserving the supplier’s enrollment and operational capacity. A reasonable structure should address both financial recovery and how the supplier will remedy the root cause.

• Define the scope narrowly. The agreement should state that it resolves only the claims identified in the review and does not constitute a blanket finding about the supplier’s overall compliance history.
• Clarify the effect on status. Before signing, the supplier should seek explicit language confirming that the deal is not, in itself, a revocation or a suspension of enrollment. Where possible, the agreement should preserve the supplier’s right to continue billing for unrelated claims.
• Include a realistic corrective action component. A corrective action plan should be time-bound and measurable, covering documentation training, front-end claim review, and a recurring internal audit schedule.
• Negotiate an appeal waiver carefully. Waiving appeal rights can be acceptable if the deal provides sufficient concessions, but the supplier should avoid waiving rights that would otherwise protect them from future, unrelated actions.
• Add a release for the specific claim period. Ideally, the agreement includes a release of liability for the claims at issue, with clear statement that Medicare will not seek additional recoupment for those same services.

Likely Impact on the Supplier’s Business

A well-structured compliance deal can allow a supplier to continue operating while demonstrating to the Medicare contractor that the business has returned to full compliance. The impact extends beyond the billing department. Suppliers under a compliance agreement will often need to invest in compliance training, modify claims management systems, and report regularly to the contractor.

Conversely, a poorly structured deal can have a chilling effect on cash flow. Repayment agreements that demand accelerated deadlines without regard for the supplier’s Medicare cash flow cycle can jeopardize operations. Suppliers should consider negotiating repayment terms that align with their expected receivables, such as extending the payback period over a mutually agreed timeframe.

What to Watch Next

The regulatory environment for DMEPOS suppliers is not static. Suppliers should monitor changes in CMS payment policies, the expansion of prior authorization requirements, and the outcome of various court challenges to Medicare enrollment revocation procedures.

Policy attention is also turning toward supplier compliance with the face-to-face requirement and the proper use of verbal orders. As data systems improve, expectations for electronic documentation exchange are likely to increase, meaning a compliance deal that addresses only current documentation gaps will need to be forward-looking.

Suppliers should prepare for the possibility that Medicare will require more transparent disclosure of owners and delegated management entities. Any compliance deal today should be structured with an eye toward future regulatory standards, so that the corrective action plan can adapt to new expectations without reopening the settlement.

Finally, industry observers should watch how CMS handles supplier appeals, particularly the capacity of administrative law judges to hear revocation cases. If appeals slowdown, suppliers may face longer periods of uncertainty from a compliance deal that includes revocation, which could affect the industrywide approach to settlement negotiation.